CYP2C9 antibody
(1 reference)-
- Target See all CYP2C9 Antibodies
- CYP2C9 (Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9))
-
Reactivity
- Human, Mouse
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This CYP2C9 antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Cross-Reactivity
- Human, Mouse
- Purification
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human CYP2C9
- Isotype
- IgG
-
anti-Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) (AA 82-110), (N-Term) antibody
CYP2C9 Reactivity: Human WB Host: Mouse Monoclonal 682CT5-6-2 unconjugated
anti-Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) (AA 82-110), (N-Term) antibodyCYP2C9 Reactivity: Human WB, IHC (p) Host: Rabbit Polyclonal RB16653 unconjugated
anti-Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) (AA 235-265) antibodyCYP2C9 Reactivity: Human WB, IHC (p) Host: Rabbit Polyclonal RB17007 unconjugated
anti-Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) antibodyCYP2C9 Reactivity: Human, Mouse IHC, IF Host: Rabbit Polyclonal unconjugated
anti-Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) antibodyCYP2C9 Reactivity: Human IHC, ELISA Host: Rabbit Polyclonal unconjugated
anti-Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) (C-Term) antibodyCYP2C9 Reactivity: Human, Horse WB Host: Rabbit Polyclonal unconjugated
-
- Application Notes
-
WB(1:100-500)
Optimal working dilution should be determined by the investigator. - Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 1 % BSA, 50 % glycerol and 0.09 % sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- -20 °C
- Storage Comment
- Store at -20°C for 12 months.
- Expiry Date
- 12 months
-
-
: "Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation." in: Oncotarget, Vol. 8, Issue 9, pp. 15377-15392, (2017) (PubMed).
-
: "Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation." in: Oncotarget, Vol. 8, Issue 9, pp. 15377-15392, (2017) (PubMed).
-
- Target
- CYP2C9 (Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9))
- Alternative Name
- CYP2C9 (CYP2C9 Products)
- Synonyms
- CPC9 antibody, CYP2C antibody, CYP2C10 antibody, CYPIIC9 antibody, P450IIC9 antibody, cytochrome P450 family 2 subfamily C member 9 antibody, CYP2C9 antibody
- Background
-
Synonyms: CPC9, CYP2C, CYP2C10, CYPIIC9, P450IIC9, Cytochrome P450 2C9, (R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, Cytochrome P-450MP, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, S-mephenytoin 4-hydroxylase, CYP2C9
Background: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.
- Molecular Weight
- 59kDa
- Gene ID
- 1559
- UniProt
- P11712
-
